Clinical Study of Capecitabine, Oxaliplatin and Bevacizumab in Colorectal Cancer

ABSTRACT: This study will evaluate the efficacy, safety and pharmacokinetics of capecitabine (2000 mg/m2/day by mouth [po], day 1 pm-day 15 am every 3 weeks [q3w]), oxaliplatin (130 mg/m2 intravenously [iv], day 1 q3w) and bevacizumab (7.5 mg/kg iv, day 1 q3w) in patients with advanced and/or metastatic colorectal cancer.

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2030388 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR